An observational study in Atrial Fibrillation and Anticoagulant-induced Bleeding, sponsored by Arianna Anticoagulazione Foundation. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-20.
Sponsored by Arianna Anticoagulazione Foundation · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 252 studies in Atrial Fibrillation with a site in Italy — 44 open to participants now, 64 under way, 2 of them phase 3. Atrial Fibrillation · Italy.
Among the 252 studies in Atrial Fibrillation with a site in Italy, this one is the 16th largest by enrollment of the 95 observational ones that give a count, is one of 16 that started in 2018, is one of 95 observational ones, and was the 131st registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →44 of the 252 studies in Atrial Fibrillation with a site in Italy are open now. Recruiting first, the newest first:
Hospital Universitari Vall d'Hebron Research Institute · Sites in Italy, Belgium, Germany and 3 more countries
Ages 18+
Bayer · Sites in Italy, United States, Belgium and 5 more countries
Ages 18–85
Mitera Hospital · Sites in Italy, Croatia, Czechia and 5 more countries
Ages 18+
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+
Boston Scientific Corporation · Sites in Italy, Belgium, Croatia and 2 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
252 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 13 · Phase 3 44 · Phase 4 20
First in 2000; this study’s year is marked. 16 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,000 is above the median of 300 across 1,405 observational studies indexed under Atrial Fibrillation.
Median enrollment 321 across the 156 interventional studies, 411 across the 95 observational. Of the 154 that completed or were terminated, 72 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
129 of 252 have an industry lead sponsor. The 10 most frequent:
Arianna Anticoagulazione Foundation is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Arianna Anticoagulazione Foundation has 1 study filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
22 of the studies in Atrial Fibrillation with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT07901699Società Italiana di Medicina InternaResumption of Anticoagulation After Major Gastrointestinal Bleeding in Patients With Atrial Fibrillation | 2026-11 |
| NCT05005949Medtronic Cardiac Ablation SolutionsSTOP Persistent AF PAS | 2026-12 |
| NCT07429214Biosense Webster, Inc.A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF | 2026-12-30 |
| NCT07428564Biosense Webster, Inc.A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE PRO Software in Participants With PsAF | 2026-12-30 |
Add all 22 to your calendar (.ics) → With an account.
Among the 252 studies in Atrial Fibrillation with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The MAS Study is an observational, multicentre, prospective cohort study in Non valvular Atrial fibrillation (NVAF) patients treated with one of the direct oral anticoagulants (DOACs) available in Italy for NVAF patients.
The general aim is to deepen the knowledge of DOAC treatment in NVAF patients, by measuring the plasma concentration of anticoagulant drugs and their correlation with any adverse events that may occur during treatment.
The MAS Study is an observational, prospective cohort study, double blind, multicentre, international and no Profit. Anticoagulation clinics, affiliated or not to the Italian FCSA, will be asked to take an active part in the study, provided they have the facilities for blood sampling and processing.
4000 consecutive NVAF outpatients, 1000 for each single drug, starting anticoagulation with one of the four DOAC (apixaban, dabigatran, edoxaban, rivaroxaban) will be enrolled at the moment of the first prescription. Patients will receive the type and dosage of DOAC on the base of clinical characteristics at the discretion of the attending physician, as the normal clinical practice, and the study will not influence the decision of the type and dosage of DOAC.
The primary study objective is to evaluate the possible relationship between DOAC anticoagulant levels at the trough, measured at steady state (within the first 2-4 weeks of treatment) and occurrence of bleeding and thromboembolic events during the subsequent one year follow up
4000 consecutive Non Valvular Atrial Fibrillation outpatients, 1000 for each single drug, aged >18 years and starting anticoagulation with one of the four DOAC (apixaban, dabigatran, edoxaban, rivaroxaban) will be enrolled at the moment of the first prescription. Patients will receive the type and dosage of DOAC on the base of clinical characteristics at the discretion of the attending physician, as the normal clinical practice, and the study will not influence the decision of the type and dosage of DOAC
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Number and rate of major bleeding events and clinically relevant bleeds (defined according to International Society on Thrombosis and Haemostasis guidelines)
Fatal bleeding; Acute clinically overt bleeding;intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal will be recorded in all patients.
Time frame: From date of enrollment until the date of first documented event assessed up to 12 months
Number and rate of patients with confirmed thromboembolic and thromboembolic-related dath
Cardiovascular event: transient ischemic attack, stroke. myocardial infarction; the occurrence of deep vein thrombosis with or without pulmonary embolism will be recorded in all patients.
Time frame: From date of enrollment until the date of first documented event assessed up to 12 months
Number and rate of death patients (overall mortality)
Cardiovascular related death; thromboembolic related dath, bleeding-related death, cancer related death will be recorded in all patients
Time frame: From date of enrollment until the date of first documented event assessed up to 12 months
Through plasma concentration (ng/ml) of Apixaban, Dabigatran, Edoxaban and Rivaroxaban
Blood sampling is performed at trough level for each anticoagulant drug used after the last dose intake of dabigatran, apixaban, rivaroxaban and edoxaban
Time frame: 15-20 days after the enrollment
Number and rate of patients who discontinued treatment
The treatment withdrawal, either for patients or for physician decision-making will be recorded in all patients
Time frame: From date of enrollment until the date of first documented event assessed up to 12 months
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2018 to primary completion in May 2022, 45 months.
Of 552 non-industry observational studies under Atrial Fibrillation, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 91. This study's 45 months is close to that.
Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Arianna Anticoagulazione Foundation